🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of 3D Magnetic Resonance Spirometry: Comparison with Spirometry in Healthy Subjects and Patients with Respiratory Pathologies (asthma, COPD, Bilateral Lung Transplant)

RecruitingNAAges 18 Years - 90 YearsAllCommissariat A L'energie Atomique
NCT05724745 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Spirometry is now the gold standard technique for assessing lung function in humans. From the shape of a flow-volume curve measured while the patient, trained by the practitioner, performs forced breaths, the forced vital capacity (FVC) and the forced expiratory volume in one second (FEV1) can be deduced and the pulmonologist is able to detect and characterize respiratory diseases as well as to evaluate current treatments. This technique is non-invasive and simple. It is widely available, robust, reproducible and sensitive to intervention. However, it requires proactive cooperation from the patient and only measures global pulmonary ventilation, without locoregional information. An innovative strategy and an original study framework have been developed in the BioMaps laboratory to establish local maps of flow-volume curves across the lung and to jointly analyze ventilatory function and

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Generic inclusion criteria * Ability to understand the nature and objectives of the study * Ability to remain immobile in an MRI scanner in supine position for the entire duration of the acquisitions * Ability to give free and informed written consent Specific inclusion criteria for healthy volunteers * Age: 18-45 years * No known and diagnosed pulmonary pathology such as respiratory insufficiency, COPD, asthma or cancer * Ability to remain motionless in an MRI scanner in a prone position for a total of 50 min. * Non-smoker and non-smoker Specific inclusion criteria for asthma patients * Age: 18-80 years * Asthma of varying degrees of severity, depending on inhalation required to achieve control: * Diagnosis of asthma classified as moderate according to the Global initiative for asthma (GINA) guidelines for at least 6 months * Diagnosis of asthma classified as severe according to the Global initiative for asthma (GINA) guidelines for at least 6 months months with initiation of biotherapy planned by their pulmonologist * Non-smoker and non-vapourist Specific inclusion criteria for COPD patients * Age: 40-80 years * COPD of varying degrees of severity: * Diagnosis of COPD classified as moderate according to the Global initiative for chronic obstructive lung disease guidelines (GOLD 2: VEMS = 50-79%) * Diagnosis of COPD classified as severe according to the guidelines for chronic obstructive lung disease (GOLD 3: VEMS = 30-49%) Specific inclusion criteria for patients with bilateral lung transplants with BOS * Age: 18-90 years * Irreversible FEV1 \< 80% of baseline with FEV1/FVC ratio FEV1/FVC \< 0.7 * Absence of visible parenchymal opacity on CT scan (non inclusion of mixed RAS/CLAD) * Absence of significant bronchial stenosis (having required endoscopic endoscopic treatment) * No diaphragmatic involvement (established by sniff test under fluoroscopy fluoroscopy or diaphragmatic ultrasound) Specific inclusion criteria for patients with bilateral lung transplants without BOS * Age: 18-90 years * FEV1 \> 90% baseline for more than 24 months after the date of date of lung transplantation * Absence of significant bronchial stenosis (requiring endoscopic endoscopic treatment) * Absence of diaphragmatic impairment (established by sniff test under fluoroscopy or diaphragmatic ultrasound)
💊

What it tests

  • 1. Standard spirometry
  • 2. 3D dynamic lung MRI at UTE in prone and supine positions
  • 3. Reversibility test with salbutamol
  • 4. 3D dynamic lung MRI at UTE in supine and prone position
📍

Where

1 site
CEA | Service Hospitalier Fréderic Joliot
Orsay, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy